Tilray, Inc. (TLRY) financial analysis and rating
Comparison analysis based on SEC data
| Company Name | Tilray, Inc. |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products |
| Latest report | 12/31/2019 (filed 3/02/2020) |
| Revenue | $154 million (ranked #167 out of 515 companies in the industry) |
| Assets | $896 million (ranked #122) |
Financial position and performance
| Compared with industry ratios | Change during the year |
|---|---|
|
worse |
deteriorated |
| Compared with all industry ratios |
|---|
|
worse |
Financial ratios benchmarking
| Finanancial ratio | Compared | ||
|---|---|---|---|
|
with industry ratios (28 - Chemicals And Allied Products) |
with all industry ratios | ||
| Solvency Ratios | |||
| Debt ratio |
0.68
0.44 |
0.68
0.61 | |
| Debt-to-equity ratio |
2.14
0.39 |
2.14
1.12 | |
| Interest coverage ratio |
-889.86
-8.75 |
-889.86
2.20 | |
| Liquidity Ratios | |||
| Current Ratio |
2.80
3.42 |
2.80
1.69 | |
| Quick Ratio |
1.05
2.10 |
1.05
1.08 | |
| Cash Ratio |
1.05
2.55 |
1.05
0.51 | |
| Profitability Ratios | |||
| Profit margin |
-208.8%
-129.5% |
-208.8%
4% | |
| ROE (Return on equity), after tax |
-133%
-67.6% |
-133%
2.7% | |
| ROA (Return on assets) |
-41.4%
-40.8% |
-41.4%
1% | |
| Activity Ratios | |||
| Asset turnover (days) |
1842
1223 |
1842
747 | |
| Receivables turnover (days) |
20
56 |
20
50 | |
| Resulting score | -0,8 | -0,7 | |
Additional ratios (not used to calculate the resulting score)
| Finanancial ratio | Compared | ||
|---|---|---|---|
|
with industry ratios (28 - Chemicals And Allied Products) |
with all industry ratios | ||
| Profitability Ratios | |||
| Gross margin |
-15.3%
53.5% |
-15.3%
42.2% | |
| Operating margin (Return on sales) |
-214%
-36.4% |
-214%
8% | |
| Activity Ratios | |||
| Inventory turnover (days) |
1446
121 |
1446
71 | |
| EBIT | $(329)M | ||
| EBITDA | $(313)M | ||
Auditor's conclusion
We have conducted a comparative analysis of the balance sheet and the income statement of Tilray, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). The primary business activity of the company is Medicinal Chemicals and Botanical Products (SIC code 2833). During the analysis we have compared the key financial ratios of the company with the average (median) values of those ratios calculated for the specific industry sector and for all industries. The averages are calculated using the data from financial statements for the year 2019 submitted to the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics with the median value, we have made a generalized conclusion about the quality of the financial condition of the company. Calculations and summary conclusions are made in a computerized way using software and methods developed by Consulting financial and analytical company Ankon.
As a result of the analysis of the key financial ratios of the company, we have established the following. The financial condition of Tilray, Inc. in 2019 is worse than the financial condition of half of all companies engaged in the activity "Medicinal Chemicals and Botanical Products"
Comparison of the Company’s financial ratios with average ratios for all business activities leads to the same conclusion. The financial position of Tilray, Inc. is worse than that of most listed companies that submit financial statements to the U.S. Securities and Exchange Commission.
Additional data about Tilray, Inc.
Closest competitors
| Company | USD ($), in Millions | |
|---|---|---|
| Revenue | Assets | |
| USANA Health Sciences, Inc. | 1,061 | 517 |
| Mannatech, Incorporated | 158 | 63 |
| Natural Alternatives International, Inc. | 124 | 110 |
| ChromaDex Corporation | 46 | 40 |
See also all industry leaders
Financial data source and analysis principles
The above is a comparative analysis of the financial position and performance of the company. The comparison is based on official financial statements filed with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR) (about 10,000 largest publicly traded companies). The comparison is performed using the eleven key financial ratios (see table above). Company's financial ratios are compared with the median values of ratios of all companies and of companies within the same industry, and also with the quartiles of those ratios. Each ratio value is given a score ranging from -2 and +2 depending on its position relative to the quartiles (-2 – below the first quartile; -1 – between the first and the second quartile; +1 – between the second and the third quartile; +2 – above the third quartile; 0 – the ratio value deviates from the median by no more than 5% of the difference between the median and the quartile closest to the ratio value). To draw a conclusion from the analysis the individual scores are weighted equally to get an overall score ranging from -2 and +2.
| much better (+1 - +2incl) | |
| better (from 0.11 to +1incl) | |
| about the same (from -0.11incl to +0.11incl) | |
| worse (from -1incl to -0.11) | |
| much worse (from -2incl to -1) |
Change during the year is calculated by comparing the resulting score of financial position within the industry with the last year's (quarter's) score. The result of the comparison may be as follows:
| improved considerably (positive change of more than 1 point) | |
| improved (positive change of less than 1 point) | |
| unchanged (little or no change in score, no more than 0.11 points) | |
| deteriorated (the score has decreased by less than 1 point during the year) | |
| deteriorated considerably (the score has decreased by more than 1 point during the year) |
Please note: The presented analysis does not indicate a poor or good financial position of the company, but gives its description relative to other U.S. businesses. For a detailed financial analysis please use "ReadyRatios Financial Analysis" - load the data into the program>>